An interventional study of AI-Based Conversational Social Support and Community Social Participation in Heart Failure, sponsored by Chang Gung University of Science and Technology. Recruiting at 2 sites in Taiwan. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Chang Gung University of Science and Technology · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 137 studies in Heart Failure with a site in Taiwan — 30 open to participants now, 39 under way, 14 of them phase 3. Heart Failure · Taiwan.
Among the 137 studies in Heart Failure with a site in Taiwan, this one is the 52nd largest by planned enrollment of the 101 interventional ones that give a count, is one of 10 that started in 2025, is one of 49 with no phase, reaches primary completion later than 26 of the 38 other live ones, and was the 137th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →30 of the 137 studies in Heart Failure with a site in Taiwan are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Taiwan, United States, Argentina and 29 more countries
Ages 18+
Bayer · Sites in Taiwan, United States, Argentina and 20 more countries
Ages up to 18
Novo Nordisk A/S · Sites in Taiwan, United States, Argentina and 24 more countries
Ages 18+
National Defense Medical Center, Taiwan · Sites in Taiwan
Ages 20–90 · Healthy volunteers
National Taiwan University Hospital · Sites in Taiwan
Ages 18+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
137 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 11 · Phase 3 34 · Phase 4 9
First in 2006; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 174 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 177 across the 101 interventional studies, 200 across the 36 observational. Of the 73 that completed or were terminated, 35 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 137 have an industry lead sponsor. The 10 most frequent:
Chang Gung University of Science and Technology is the lead sponsor of 43 studies on the registry; 15 are open to participants now.
Chang Gung University of Science and Technology has 3 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
6 of the studies in Heart Failure with a site in Taiwan that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT06008197Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | 2027-11 |
| NCT07068308National Yang Ming Chiao Tung UniversityEffects of a Wed-based FRAIL-SM Program Among Patients With Heart Failure | 2027-05-31 |
| NCT06968533National Defense Medical Center, TaiwanECG Low Ejection Fraction Detection and Guiding in AI Navigated Treatment Era | 2027-06-01 |
| NCT07798856Chimei Medical CenterEffects of a Multidisciplinary Integrated Care Model on Care Outcomes in Patients With Heart Failure With Preserved Ejection Fraction | 2027-07 |
Add all 6 to your calendar (.ics) → With an account.
Among the 137 studies in Heart Failure with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This three-year study aims to investigate gender differences in social frailty and evaluate the effects of an artificial intelligence (AI)-based conversational social-support intervention among older adults with chronic heart failure (CHF).
The study plans to enroll 300-500 adults aged 60 years or older from four Chang Gung Memorial Hospital branches in Taiwan.
In the first phase, researchers will assess participants' clinical characteristics, sarcopenia, physical activity, and physical, psychological, and social frailty. The study will examine gender differences and identify factors associated with social frailty.
In the second phase, 174 participants are planned to be assigned to three groups: an AI-based conversational social-support group, a community social participation group, and a control group. The AI group will engage in daily 15-30-minute app-based conversations, while the community group will be encouraged to participate in regular social activities. The control group will maintain routine activities.
The third phase will assess longer-term changes in social frailty, emotional well-being, physical activity, and health outcomes, with follow-up assessments at 1, 3, 6, and 12 months after the intervention.
This study combines an initial cross-sectional assessment with an embedded intervention trial and longitudinal follow-up.
Phase 1: Baseline assessment
Clinical information and standardized assessments will be collected to examine gender differences in sarcopenia, physical activity, and multidimensional frailty among older adults with chronic heart failure. Structural equation modeling will be used to investigate factors and pathways associated with social frailty.
Phase 2: Intervention
The protocol plans to enroll 174 participants in three groups of 58:
Clinical and questionnaire-based assessments will be conducted before and after the intervention to evaluate changes in emotional state, physical activity, social frailty, and other health outcomes.
Phase 3: Longitudinal follow-up
Follow-up assessments are planned at 1, 3, 6, and 12 months after the intervention to examine the sustainability of intervention effects and potential gender differences. Assessments include standardized questionnaires and relevant clinical measures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will receive an AI-based conversational social-support intervention delivered via a tablet.
Behavioral: AI-Based Conversational Social Support
Participants in this group will be encouraged to attend regular community social activities to enhance social interaction. Care and follow-up will also be provided by telephone.
Behavioral: Community Social Participation
Participants in this group will maintain their routine activities without receiving the AI-based conversational social-support intervention or the community social participation intervention.
Participants will receive an AI-based conversational social-support intervention delivered via a tablet. The intervention is designed to provide social interaction and support for older adults with heart failure.
Participants will be encouraged to attend regular community social activities to enhance social interaction, with continued care and follow-up by telephone.
Change in Social Frailty Score
Change in social frailty will be assessed using the five-item Makizako Social Frailty Index. Each item is scored as 0 or 1, yielding a total score ranging from 0 to 5. Higher scores indicate greater social frailty and therefore worse outcomes. Changes in scores will be compared among the AI-based conversational social-support intervention group, community social participation group, and control group.
Time frame: Baseline and 1, 3, 6, and 12 months after intervention
Plan to share: No — Individual participant data will not be shared with researchers outside the study team due to participant privacy and confidentiality considerations.
Started Nov 2025 (actual). Primary completion is estimated for Jul 2028, 32 months after the start.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 32 months is above that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chang Gung University of Science and Technology